Article ID Journal Published Year Pages File Type
8740816 Journal of Microbiology, Immunology and Infection 2018 5 Pages PDF
Abstract
The present results suggest that PIPC/TAZ is as effective as MEPM and safe for second-line treatment of FN in pediatric patients. Furthermore, IVIG appears very effective for patients with low serum IgG levels.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Immunology
Preview
Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients
Authors
, , , , , ,